Back to top
more

Baxter International (BAX)

(Delayed Data from NYSE)

$35.87 USD

35.87
3,167,156

+0.17 (0.48%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $35.75 -0.12 (-0.33%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value F Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (74 out of 250)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Santanu Roy headshot

NeoGenomics and SolarEdge Technologies have been highlighted as Zacks Bull and Bear of the Day

by Santanu Roy

NeoGenomics and SolarEdge Technologies are part of the Zacks Bull and Bear of the Day article.

Indrajit Bandyopadhyay headshot

3 Medical Device Stocks With Solid Dividend Yield: CAH & Others

by Indrajit Bandyopadhyay

Here we pick three medical device stocks, Cardinal Health (CAH), Baxter International (BAX) and Fresenius Medical Care (FMS), with a solid five-year dividend growth history.

Baxter's (BAX) New Launch to Enable Earlier Treatment of Eye

by Zacks Equity Research

Baxter's (BAX) latest offering is likely to enable a more digitally-connected primary care examination and support faster diagnosis for earlier treatment of eye conditions.

Andrew Rocco headshot

The 3 Widest Competitive Moats on Wall Street

by Andrew Rocco

Competitive moats symbolize a company's sustainable advantage, protecting it from competitors and external threats. Three standout examples illustrate this principle vividly.

Reasons to Retain Baxter International (BAX) in Your Portfolio

by Zacks Equity Research

Baxter International's (BAX) robust growth across all geographies, along with transformational initiatives, boosts confidence. However, pandemic-related disruption continues to hurt sales.

Rockwell Medical (RMTI) to Post Q2 Earnings: What's in Store?

by Zacks Equity Research

Robust product demand and cost-saving initiatives are likely to have boosted Rockwell Medical's (RMTI) second quarter's top line.

Baxter (BAX) Beats on Q2 Earnings, Revises 2023 EPS Guidance

by Zacks Equity Research

Baxter's (BAX) second-quarter 2023 results reflect sustained demand for its medically essential products amid a stabilizing macroeconomic climate and healthcare marketplace.

Baxter (BAX) Reports Q2 Earnings: What Key Metrics Have to Say

by Zacks Equity Research

Although the revenue and EPS for Baxter (BAX) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Baxter International (BAX) Lags Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Baxter (BAX) delivered earnings and revenue surprises of -6.78% and 2.29%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Baxter (BAX) to Post Q2 Earnings: What's in the Offing?

by Zacks Equity Research

Baxter's (BAX) second-quarter results are likely to reflect growth in elective surgical procedures, offset by currency movement. Hillrom's products might have boosted sales.

Earnings Preview: Baxter International (BAX) Q2 Earnings Expected to Decline

by Zacks Equity Research

Baxter (BAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Baxter's (BAX) New Launch to Support Complex Critical Care Needs

by Zacks Equity Research

Baxter's (BAX) Progressa+ bed for the ICU is expected to enhance workflow and reduce strain on nursing resources.

How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings

by Zacks Equity Research

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

Strength Seen in Valneva SE Sponsored ADR (VALN): Can Its 15.8% Jump Turn into More Strength?

by Zacks Equity Research

Valneva SE Sponsored ADR (VALN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

BAX vs. SYK: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

BAX vs. SYK: Which Stock Is the Better Value Option?

Ensign Group (ENSG) Beats on Q1 Earnings, Hikes '23 EPS View

by Zacks Equity Research

Ensign Group's (ENSG) first-quarter results benefit from growing skilled services revenues. Management estimates EPS of $4.64-$4.77 for this year, higher than the earlier mentioned $4.60-$4.74.

Baxter (BAX) Beats on Q1 Earnings, Ups '23 EPS View

by Zacks Equity Research

Baxter's (BAX) first-quarter 2023 results reflect sustained demand for its medically essential products amid a stabilizing macroeconomic climate and healthcare marketplace.

Baxter International (BAX) Q1 Earnings and Revenues Top Estimates

by Zacks Equity Research

Baxter (BAX) delivered earnings and revenue surprises of 22.92% and 1.47%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Medical Device Stocks' Q1 Earnings on Apr 27: WST, DXCM, BAX

by Zacks Equity Research

Medical Device companies' Q1 results are likely to reflect strength in customer demand. Let's see how WST, DXCM and BAX are placed ahead of their earnings releases.

Are Investors Undervaluing Baxter International (BAX) Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Baxter (BAX) to Post Q1 Earnings: What's in the Offing?

by Zacks Equity Research

Baxter's (BAX) first-quarter results are likely to reflect growth in elective surgical procedures, offset by currency movement. Hillrom's products might have boosted sales.

Baxter's (BAX) New Premix Drug Now Available in the U.S.

by Zacks Equity Research

Baxter's (BAX) latest frozen premix formulation is expected to support patient safety, simplify medication preparation and boost operational efficiencies.

Baxter (BAX) Q4 Earnings Miss Estimates, FY23 Outlook Weak

by Zacks Equity Research

Baxter's (BAX) fourth-quarter results reflect impact of additional sales from the legacy Hilrom's business acquired in 2021. Ongoing macroeconomic challenges hurt earnings significantly.

Baxter International (BAX) Lags Q4 Earnings Estimates

by Zacks Equity Research

Baxter (BAX) delivered earnings and revenue surprises of -6.38% and 3.05%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Quipt Home Medical Corp. (QIPT) to Report Q1 Results: Wall Street Expects Earnings Growth

by Zacks Equity Research

Quipt Home Medical Corp. (QIPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.